NCT05165407: Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
- State
- Under way
- Phase
- Phase 2
- People
- 30 planned
- Started
- 12 Jul 2022
- Primary completion
- Sep 2025
- Arms
- Sintilimab Combined With IBI310 and Surufatinib
- Results
- None posted
- 21 Dec 2021: Trial registered
- 12 Jul 2022: Trial started